Mubadala Capital, the wholly-owned alternative asset management subsidiary of Abu Dhabi-headquartered Mubadala Investment Company and Temasek-owned asset management group, Seviora Holdings, have ...

Seviora Holdings, an asset management arm of Temasek, Singapore, signed an agreement with Mubadala Capital, the alternative asset management subsidiary of Mubadala Investment Co., Abu Dhabi ...

Mubadala Investment Company's Mubadala Capital and Seviora Holdings, a unit of Singapore state investor Temasek, are forming a partnership to identify and pursue co-investment opportunities, according ...

Manipal Hospitals, the Indian hospital chain majority owned by Singapore state investment firm Temasek, is actively evaluating acquisition opportunities across southern states and has identified about ...

NEW YORK, NY / ACCESSWIRE / October 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alto Neuroscience, Inc. ("Alto Neuroscience, Inc.") (NYSE:ANRO) concerning ...

Fintel reports that on October 23, 2024, Wedbush downgraded their outlook for Alto Neuroscience (NYSE:ANRO) from Outperform to Neutral. Analyst Price Forecast Suggests 636.93% Upside As of October ...

On Tuesday, Alto Neuroscience, Inc. (NYSE:ANRO) revealed that the Phase 2b study of ALTO-100 for major depressive disorder (MDD) did not meet its primary endpoint compared to placebo. The ...

Alto Neuroscience (NYSE:ANRO) shares nosedived 66% Wednesday morning, the first trading session, after the company announced its psychiatric drug ALTO-100 had failed a key clinical study.

ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Alto Neuroscience, Inc. (ANRO – Research Report), with a price target of $32.00. The company’s shares ...